ZA202401319B - Hepatitis b virus (hbv) knockouts - Google Patents
Hepatitis b virus (hbv) knockoutsInfo
- Publication number
- ZA202401319B ZA202401319B ZA2024/01319A ZA202401319A ZA202401319B ZA 202401319 B ZA202401319 B ZA 202401319B ZA 2024/01319 A ZA2024/01319 A ZA 2024/01319A ZA 202401319 A ZA202401319 A ZA 202401319A ZA 202401319 B ZA202401319 B ZA 202401319B
- Authority
- ZA
- South Africa
- Prior art keywords
- knockouts
- hbv
- hepatitis
- virus
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10161—Methods of inactivation or attenuation
- C12N2730/10162—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163224581P | 2021-07-22 | 2021-07-22 | |
| PCT/US2022/073981 WO2023004375A2 (en) | 2021-07-22 | 2022-07-21 | Hepatitis b virus (hbv) knockouts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202401319B true ZA202401319B (en) | 2025-05-28 |
Family
ID=84978767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2024/01319A ZA202401319B (en) | 2021-07-22 | 2024-02-12 | Hepatitis b virus (hbv) knockouts |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240350665A1 (enExample) |
| EP (1) | EP4373518A2 (enExample) |
| JP (1) | JP2024529400A (enExample) |
| KR (1) | KR20240087635A (enExample) |
| CN (1) | CN118355348A (enExample) |
| AU (1) | AU2022315298A1 (enExample) |
| CA (1) | CA3226445A1 (enExample) |
| IL (1) | IL310290A (enExample) |
| WO (1) | WO2023004375A2 (enExample) |
| ZA (1) | ZA202401319B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026523341A (ja) | 2023-05-15 | 2026-07-14 | エヌクロマ・バイオ，インコーポレーテッド | Ｈｂｖ遺伝子発現のエピジェネティック調節のための組成物および方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105899658B (zh) * | 2013-12-12 | 2020-02-18 | 布罗德研究所有限公司 | 针对hbv和病毒性疾病以及障碍的crispr-cas系统和组合物的递送、用途和治疗应用 |
| WO2016197132A1 (en) * | 2015-06-04 | 2016-12-08 | Protiva Biotherapeutics Inc. | Treating hepatitis b virus infection using crispr |
| KR101842131B1 (ko) * | 2016-09-05 | 2018-03-27 | 연세대학교 산학협력단 | Hbv를 표적으로 하는 유전자 가위 및 이를 포함하는 hbv 감염 치료용 조성물 |
| JP7679309B2 (ja) * | 2019-05-10 | 2025-05-19 | ビーム セラピューティクス インク． | Ｂ型肝炎を治療するための組成物及び方法 |
-
2022
- 2022-07-21 AU AU2022315298A patent/AU2022315298A1/en not_active Abandoned
- 2022-07-21 IL IL310290A patent/IL310290A/en unknown
- 2022-07-21 CN CN202280063407.1A patent/CN118355348A/zh active Pending
- 2022-07-21 WO PCT/US2022/073981 patent/WO2023004375A2/en not_active Ceased
- 2022-07-21 JP JP2024503721A patent/JP2024529400A/ja active Pending
- 2022-07-21 US US18/291,051 patent/US20240350665A1/en active Pending
- 2022-07-21 KR KR1020247005820A patent/KR20240087635A/ko active Pending
- 2022-07-21 EP EP22846827.8A patent/EP4373518A2/en active Pending
- 2022-07-21 CA CA3226445A patent/CA3226445A1/en active Pending
-
2024
- 2024-02-12 ZA ZA2024/01319A patent/ZA202401319B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN118355348A (zh) | 2024-07-16 |
| CA3226445A1 (en) | 2023-01-26 |
| AU2022315298A1 (en) | 2024-02-22 |
| WO2023004375A3 (en) | 2023-04-13 |
| US20240350665A1 (en) | 2024-10-24 |
| KR20240087635A (ko) | 2024-06-19 |
| EP4373518A2 (en) | 2024-05-29 |
| IL310290A (en) | 2024-03-01 |
| JP2024529400A (ja) | 2024-08-06 |
| WO2023004375A2 (en) | 2023-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY201997A (en) | Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof | |
| EA201791991A1 (ru) | Способ улучшения способности противодействовать внедренным днк-содержащим вирусам растения | |
| EP4455285A3 (en) | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof | |
| MX2024006956A (es) | Inserciones de adn no virales orientadas. | |
| CN111278980A (zh) | 一种基因编辑系统及基因编辑的方法 | |
| WO2019103442A3 (ko) | CRISPR/Cpf1 시스템을 이용한 유전체 편집용 조성물 및 이의 용도 | |
| NZ563845A (en) | RNAi sequences against the Influenza A segment 1 PB2 gene and uses thereof as anti-viral therapeutic | |
| CY1114192T1 (el) | Λεντι-ιικος φορεας | |
| WO1996021731A3 (en) | Stabilized external guide sequences | |
| GB0326798D0 (en) | Methods for generating mutant virus | |
| ATE450621T2 (de) | Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind | |
| PL358982A1 (pl) | Oligodezoksynukleotydy jako immunostymulatory | |
| BRPI0411219A (pt) | seqüências de hbv e hcv conservadas úteis para silenciamento de gene | |
| WO2003087301A8 (en) | Methods and compositions for dna manipulation | |
| PH12021552870A1 (en) | Compositions and methods for treating hepatitis b virus (hbv) infection | |
| AU2021216418A8 (en) | Compositions and methods for targeting, editing or modifying human genes | |
| UA108902C2 (uk) | Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування | |
| WO2006121464A3 (en) | Compositions for treating respiratory viral infections and their use | |
| PH12021551025A1 (en) | 5-halouracil-modified micrornas and their use in the treatment of cancer | |
| ATE491471T1 (de) | Adjuvantien für dns impstoffe basierend auf imidazochinoline | |
| WO2023004375A3 (en) | Hepatitis b virus (hbv) knockouts | |
| EP4567109A3 (en) | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome | |
| TR201820474T4 (tr) | Spesifik immün modülatör profilleri indükleyen tanımlı nükleotitler arası bağlar bağlamında rna sekansı motifleri. | |
| GB2376687B (en) | Herpes viruses for immune modulation | |
| HRP20090230T1 (hr) | Replikacijski-defektni rna virusi kao cjepiva |